Value of thyroid transcription Factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma

American Journal of Surgical Pathology

Volumn 24, Issue 4, 2000, Pages 598-606

  Ordóñez, Nelson G ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BG8; CD44S; E cadherin; Immunohistochemistry; Mesothelioma; Thyroid transcription factor; WT1

Indexed keywords

THYROID TRANSCRIPTION FACTOR 1; TUMOR MARKER; UVOMORULIN;

ARTICLE; CANCER DIAGNOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; PLEURA MESOTHELIOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANTIGENS, CD44; CADHERINS; DIAGNOSIS, DIFFERENTIAL; DNA-BINDING PROTEINS; EPITHELIAL CELLS; HUMANS; LEWIS BLOOD-GROUP SYSTEM; LUNG NEOPLASMS; MESOTHELIOMA; NUCLEAR PROTEINS; PLEURAL NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 0343238145     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-200004000-00016     Document Type: Article

References (56)

1. Afify AM, Stern R, Jobes GA, Bailey JL, Werness BA. Differential expression of CD44S and hyaluronic acid in malignant mesotheliomas, adenocarcinomas, and reactive mesothelial hyperplasias. Appl Immunohistochem 1998;6:11-5.
2. Amin KM, Litzky LA, Smythe WR, et al. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 1995;146:344-56.
3. Attanoos RL, Goddard H, Gibbs AR. Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma. Histopathology 1996; 29:209-15.
4. Attanoos RL, Webb R, Gibbs AR. CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma. Histopathology 1997;30:260-3.
5. Bejarano PA, Baughman RP, Biddinger PW, et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol 1996;9:445-52.
6. Bohinski RJ, Di Lauro R, Whitsett JA. The lung-specific protein B promoter is a target for thyroid transcription factor 1 and hepatocyte nuclear factor 3, indicating common factors for organ specific gene expression along the foregut. Mol Cell Biol 1994;14:5671-81.
7. Brown RW, Clark GM, Tandon AK, Allred DC. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol 1993;24:347-54.
8. Clover J, Oates J, Edwards C. Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma. Histopathology 1997;31: 140-3.
9. Collins CL, Ordóñez NG, Schaefer R, et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am J Pathol 1992;141:827-33.
10. Di Loreto C, Di Lauro V, Puglisi F, Damante G, Fabbro D, Beltrami CA. Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma. J Clin Pathol 1997;50:30-2.
11. Di Loreto C, Puglisi F, Di Lauro V, Damante G, Beltrami CA. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung. Cancer Lett 1998;124:73-8.
12. Doglioni C, Dei Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996;20:1037-46.
13. Edwards C, Oates J. OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin-fixed and paraffin wax embedded material. J Clin Pathol 1995;48:626-30.
14. Fabbro D, Di Loreto C, Beltrami CA, Belfiore A, Di Lauro R, Damante G. Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res 1994; 54:4744-9.
15. Fabbro D, Di Loreto C, Stamerra O, Beltrami CA, Lonigro R, Damante G. TTF-1 gene expression in human lung tumours. Eur J Cancer 1996;32A:512-7.
16. Filie AC, Abati A, Fetsch P, Azumi N. Hyaluronate binding probe and CD44 in the differential diagnosis of malignant effusions: disappointing results in cytology material [Letter]. Diagn Cytopathol 1998;18:473-4.
17. Garcia-Prats MD, Ballestin C, Sotelo T, Lopez-Encuentra A, Mayordomo JI. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours. Histopathology 1998;32:462-72.
18. Gerwin BI. Asbestos and the mesothelial cell: a molecular trail to mitogenic stimuli and suppressor gene suspects. Am J Respir Cell Mol Biol 1994;11:507-8.
19. Gotzos V, Vogt P, Celio MR. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. Pathol Res Pract 1996;192:137-47.
20. Guazzi S, Price M, De Felice M, Damante G, Mattel MG, Di Lauro R. Thyroid nuclear factor 1 (TTF-1) contains a homeo-domain and displays a novel DNA-binding specificity. EMBO J 1990;9: 3631-8.
21. Han AC, Peralta-Soler A, Knudsen KA, Wheelock MJ, Johnson KR, Salazar H. Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues. Hum Pathol 1997;28:641-5.
22. Ikeda K, Clark JC, Shaw-White JR, Stahlman MT, Boutell CJ, Whitsett JA. Gene structure and expression of human thyroid transcription factor-1 in respiratory epithelial cells. J Biol Chem 1995; 270:8108-14.
23. Iwatsubo Y, Pairon JC, Archambault de Beaune C. Pleural mesothelioma: a descriptive analysis based on a case-control study and mortality data in Ile de France, 1987-1990. Am J Ind Med 1994; 26:77-88.
24. Jordon D, Jagirdar J, Kaneko M. Blood group antigens, Lewisx and Lewisy, in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma. Am J Pathol 1989;135:931-7.
25. Kennedy AD, King G, Kerr KM. HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura. J Clin Pathol 1997;50:859-62.
26. Kleymenova EV, Yuan X, LaBate ME, Walker CL. Identification of a tumor-specific methylation site in the Wilms tumor suppressor gene. Oncogene 1998;16:713-20.
27. Kumar-Singh S, Segers K, Rodeck U, et al. WT1 mutation in malignant mesothelionia and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J Pathol 1997;181:67-74.
28. Lazzaro D, Price M, De Felice M, Di Lauro R. The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the foetal brain. Development 1991;113:1093-104.
29. Leers MPG, Aarts MMJ, Theunissen PHMH. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology 1998;32:209-16.
30. McDonald JC. Health implications of environmental exposure to asbestos. Environ Health Perspect 1995;62:316-28.
31. Noguchi M, Nakajima T, Hirohashi S, Akiba T, Shimosato Y. Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, anti-Lewisa, and anti-Tn antibodies. Hum Pathol 1989;20:53-7.
32. Ordóñez NG. The immunohistochemical diagnosis of epithelial mesothelioma. Hum Pathol 1999;30:313-23.
33. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Am J Surg Pathol 1989;13:276-91.
34. Ordóñez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 1998;22:1203-14.
35. Ordóñez NG. Value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. A comparative study with other commonly used antibodies. Am J Surg Pathol 1997;21:1399-408.
36. Ordóñez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol 1998;11:929-33.
37. Ordóñez NG. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol 1998;22:1215-21.
38. Ordóñez NG. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Hum Pathol 1998;29:166-9.
39. Ordóñez NG. Value of thrombomodulin immunostaining in the diagnosis of mesothelioma. Histopathology 1997;31:25-30.
40. Ordóñez NG, Mackay B. The roles of immunohistochemistry and electron microscopy in distinguishing epithelial mesothelioma of the pleura from adenocarcinoma. Adv Anat Pathol 1996;3:273-93.
41. Oury TD, Hammar SP, Roggli VL. Ultrastructural features of diffuse malignant mesotheliomas. Hum Pathol 1998;29:1382-92.
42. Park S, Schalling M, Bernard A, et al. The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet 1993;4:415-20.
43. Peralta-Soler A, Knudsen KA, Jaurand MC, et al. The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas. Hum Pathol 1995;26: 1363-9.
44. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999;79:666-72.
45. Roggli VL, Kolbeck J, Sanfilippo F, Shelburne JD. Pathology of human mesothelioma: etiologic and diagnostic considerations. Pathol Annu 1987;22:91-131.
46. Riera JR, Astengo-Osuna C, Longmate JA, Battifora H. The immunohistochemical diagnostic panel for epithelial mesothelioma. A reevaluation after heat-induced epitope retrieval. Am J Surg Pathol 1997;21:1409-19.
47. Ruitenbeek T, Gouw ASH, Poppema S. Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells. Arch Pathol Lab Med 1994; 118:265-9.
48. Simsir A, Fetsch P, Mehta D, Zakowski M, Abati A. E-cadherin, N-cadherin, and calretinin in pleural effusions: the good, the bad, the worthless. Diagn Cytopathol 1999;20:125-30.
49. Sosolik RC, McGaughy VR, De Young BR. Anti-MOC-31: a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel. Mod Pathol 1997;10:716-9.
50. Stahlman MT, Gray ME, Whitsett JA. Expression of thyroid transcription factor-1 (TTF-1) in fetal and neonatal human lung. J Histochem Cytochem 1996;44:673-8.
51. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulators. Science 1991;251:1451-5.
52. Walker C, Rutten F, Yuan X, Pass H, Mew DM, Everitt J. Wilms' tumor suppressor gene expression in rat and human mesothelioma. Cancer Res 1994;54:3101-6.
53. Warnock ML, Stoloff A, Thor A. Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid-Schiff, monoclonal antibodies B72.3, and Leu M1. Am J Pathol 1988;133:30-8.
54. Wick MR, Loy T, Mills SE, Legier JF, Manivel JC. Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases. Hum Pathol 1990;21:759-66.
55. Wang N, Huang S, Gold P. Absence of carcinoembryonic antigen-like material in mesothelioma. An immunohistochemical differentiation from other lung cancers. Cancer 1979;44:937-43.
56. World Health Organization. The World Health Organization histological typing of lung tumors. Am J Clin Pathol 1982;77:123-36.